ArticleThe Prostate2013
Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer.
Article in The Prostate, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03397030 (Impact of a Home-based Exercise Program on Prognostic Biomarkers in Men With Prostate Cancer), which is not on this map. Cited by 114 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of a Home-based Exercise Program on Prognostic Biomarkers in Men With Prostate Cancer
Who cites it
114 citing papers in PubMed, 233 citations in OpenAlex.
- miR-483 Targeting of CTGF Suppresses Endothelial-to-Mesenchymal Transition: Therapeutic Implications in Kawasaki Disease.Circulation research · 2017Trial
- Circulating tumour cells as a window into lethality in prostate cancer.Nature reviews. Urology · 2026Review
- Tonic GABAScientific reports · 2025Article
- EMT and cancer stem cells: Drivers of therapy resistance and promising therapeutic targets.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2025Review
- Controlling fluid flow rate to separate leukocytes and cancer cells based on stiffness differences.Mikrochimica acta · 2025Article
- Biomechanics of circulating cellular and subcellular bioparticles: beyond separation.Cell communication and signaling : CCS · 2024Review
- A Capillary-Force-Driven, Single-Cell Transfer Method for Studying Rare Cells.Bioengineering (Basel, Switzerland) · 2024Article
- Compartmentalization of androgen receptors at endogenous genes in living cells.Nucleic acids research · 2023Article
- Phagocytosis-initiated tumor hybrid cells acquire a c-Myc-mediated quasi-polarization state for immunoevasion and distant dissemination.Nature communications · 2023Article
- ESS2 controls prostate cancer progression through recruitment of chromodomain helicase DNA binding protein 1.Scientific reports · 2023Article
- CTC-5: A novel digital pathology approach to characterise circulating tumour cell biodiversity.Heliyon · 2023Article
- Cell Membrane State, Permeability, and Elasticity Assessment for Single Cells and Cell Ensembles.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Identification of differentially expressed HERV-K(HML-2) loci in colorectal cancer.Frontiers in microbiology · 2023Article
- Cancer cell mechanobiology: a new frontier for cancer research.Journal of the National Cancer Center · 2022Review
- Breast cancer circulating tumor cells with mesenchymal features-an unreachable target?Cellular and molecular life sciences : CMLS · 2022Review
- Transcriptomic profiling of single circulating tumor cells provides insight into human metastatic gastric cancer.Communications biology · 2022Article
- Altered Synaptic Transmission and Excitability of Cerebellar Nuclear Neurons in a Mouse Model of Duchenne Muscular Dystrophy.Frontiers in cellular neuroscience · 2022Article
- High Expression of PDLIM2 Predicts a Poor Prognosis in Prostate Cancer and Is Correlated with Epithelial-Mesenchymal Transition and Immune Cell Infiltration.Journal of immunology research · 2022Article
- Contacts with Macrophages Promote an Aggressive Nanomechanical Phenotype of Circulating Tumor Cells in Prostate Cancer.Cancer research · 2021Article
- Suppressive Effect and Molecular Mechanism ofCancers · 2021Article
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
backgroundProstate tumors shed circulating tumor cells (CTCs) into the blood stream. Increased evidence shows that CTCs are often present in metastatic prostate cancer and can be alternative sources for disease profiling and prognostication. Here we postulate that CTCs expressing genes related to epithelial-mesenchymal transition (EMT) are strong predictors of metastatic prostate cancer.
methodsA microfiltration system was used to trap CTCs from peripheral blood based on size selection of large epithelial-like cells without CD45 leukocyte marker. These cells individually retrieved with a micromanipulator device were assessed for cell membrane physical properties using atomic force microscopy. Additionally, 38 CTCs from eight prostate cancer patients were used to determine expression profiles of 84 EMT-related and reference genes using a microfluidics-based PCR system.
resultsIncreased cell elasticity and membrane smoothness were found in CTCs compared to noncancerous cells, highlighting their potential invasiveness and mobility in the peripheral circulation. Despite heterogeneous expression patterns of individual CTCs, genes that promote mesenchymal transitioning into a more malignant state, including IGF1, IGF2, EGFR, FOXP3, and TGFB3, were commonly observed in these cells. An additional subset of EMT-related genes (e.g., PTPRN2, ALDH1, ESR2, and WNT5A) were expressed in CTCs of castration-resistant cancer, but less frequently in castration-sensitive cancer.
conclusionsThe study suggests that an incremental expression of EMT-related genes in CTCs is associated with metastatic castration-resistant cancer. Although CTCs represent a group of highly heterogeneous cells, their unique EMT-related gene signatures provide a new opportunity for personalized treatments with targeted inhibitors in advanced prostate cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.